Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1636282 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $97.87Day −2.09%Mkt cap $8.5B1Y +483.6%Off 52W high −6.9%Vol (1Y) 69.2%
Daily closing price, split-adjusted to the current basis; 2.6y shown of 664 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest14.4% of sh out |
| Days to cover9.0d |
| 13F net flow (QoQ)+1.04% |
| Top-10 13F concentration52.4% |
| Next report (est.)2026-08-03 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$0 |
| Earnings (TTM)-$179.4M |
| ROE−25.2% |
| ROIC−31.3% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+198.7% |
| 1Y+483.6% |
| Since incept. (ann.)+104.6% |
Total return through 2026-07-29 · series begins 2023-11-28. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)69.2% |
| Ann. volatility (3Y)72.8% |
| Sharpe (1Y)2.91 |
| Sharpe (3Y)1.36 |
| Max drawdown (1Y)−14.8% |
| Max drawdown (3Y)−74.0% |
| Beta (3Y vs SPY)1.15 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 11.8M | $594M | 15.00% | +1.2% |
| BlackRock, Inc. | 5.5M | $278M | 7.03% | −0.0% |
| RTW INVESTMENTS, LP | 4.2M | $210M | 5.31% | +0.0% |
| Fairmount Funds Management LLC | 4.0M | $203M | 5.12% | +0.0% |
| PERCEPTIVE ADVISORS LLC | 3.8M | $191M | 4.82% | +23.3% |
| Venrock Adviser, LLC | 3.7M | $186M | 4.69% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.1M | $154M | 3.89% | new |
| Driehaus Capital Management LLC | 2.8M | $141M | 3.55% | −3.2% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 105.4% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 12,221,682 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-05 | −$0.74 | — | — | — |
| 2024-12-31 | 2025-02-27 | — | — | $0 | — |
| 2024-09-30 | 2024-11-07 | $1.06 | +23.3% | $0 | — |
| 2024-06-30 | 2024-08-07 | $0.59 | — | $0 | −100.0% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-03 is ESTIMATED from filing cadence (median gap 90d) — not company-confirmed.
